The purpose of this study is to see if it is safe and effective to give an anti-HIV drug combination of indinavir (IDV) plus stavudine (d4T) plus lamivudine (3TC) to HIV-infected children. IDV will be given either as a powder mixed into applesauce or as capsules given on an empty stomach.
In this multicenter, open-label study patients receive a combined drug regimen of indinavir, stavudine, and lamivudine over 48 weeks. Patients are evaluated at Weeks 0, 2, 4, every 4 weeks until Week 24, and every 8 weeks thereafter until study completion. \[AS PER AMENDMENT 4/27/99: The study has been extended for an additional 48 weeks for a total of 96 weeks.\]
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Enrollment
24
UCSD Med Ctr / Pediatrics / Clinical Sciences
La Jolla, California, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
UCSF / Moffitt Hosp - Pediatric
San Francisco, California, United States
Yale Univ Med School
New Haven, Connecticut, United States
Univ of Florida Gainesville
Gainesville, Florida, United States
Univ of Florida Health Science Ctr / Pediatrics
Jacksonville, Florida, United States
Univ of Miami (Pediatric)
Miami, Florida, United States
Children's Hosp of Boston
Boston, Massachusetts, United States
North Shore Univ Hosp
Great Neck, New York, United States
Schneider Children's Hosp
New Hyde Park, New York, United States
Bellevue Hosp / New York Univ Med Ctr
New York, New York, United States
...and 9 more locations